Please assess the completion status of the following clinical trial:

Trial Title: Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA~All subjects will be outpatients.~Patients must be females with Turner's syndrome diagnosed by leukocyte karyotype~Chronologic age greater than or equal to 5 years.~Prepubertal Tanner I status. If breast development is Tanner II or III, demonstration of castrate status through measurement of serum FSH (greater than 12 MIU/ML).~All patients must be below the 10th percentile for chronologic age.~Patients must have at least 6 months accurate, growth measurements available for calculation of pre-study growth velocity. Pretreatment measurements must be obtained during a time when the patient is not receiving a potential growth-promoting agent.~Patients judged to be thyroxine deficient must have replacement which has resulted in normal thyroid function tests over the three-month period prior to enrollment (T4, T3, Thyroid Stimulating Hormone).~Patients and/or parents or legal guardians of patients must sign an informed consent statement. Assent should be obtained from all patients competent to understand the protocol. Local IRB requirements apply.~EXCLUSION CRITERIA~Patients who have received any form of human growth hormone within the past 3 months, or who have received a cumulative course of therapy totaling greater than one year.~Patients who have received treatment with estrogen or androgen in the past three months or who have received a cumulative course of therapy totaling greater than one year.~Patients who have any Y component in their chromosome analysis.~Patients with a chronologic age greater than 12 years.~Patients with a bone age greater than 12 years.~Patients who have clinically significant cardiac, pulmonary, gastrointestinal, hepatic or renal disease or who have had any malignancy.~Patients who have significant hematuria or proteinuria in pretherapy evaluation.~Patients who have diabetes mellitus.~Patients who have any active chronic infection (tuberculosis).~Patients who are taking amphetamines or any other drugs known to interfere with growth hormone secretion or actions.~Patients who are poor medical, psychological, or psychiatric risks for whom, in the opinion of the principal investigator, the investigational drug would be unwise.~Patients whose parents are substance abusers, nor those who come from homes in which appropriate emotional development may be limited.~Patients who cannot be seen on the schedule required by the protocol.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).